Working... Menu

A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00528333
Recruitment Status : Completed
First Posted : September 12, 2007
Last Update Posted : January 7, 2015
Information provided by (Responsible Party):
Seattle Genetics, Inc.

Brief Summary:
The purpose of this study is to assess whether there is a survival benefit with lintuzumab given in combination with low dose cytarabine versus low dose cytarabine and placebo in patients with AML.

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia Drug: Lintuzumab (SGN-33) Drug: Low dose cytarabine Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 211 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase IIB, Randomized, Double-Blinded, Placebo-Controlled Study of Low Dose Cytarabine and Lintuzumab Compared to Low Dose Cytarabine and Placebo in Patients 60 Years of Age and Older With Previously Untreated AML
Study Start Date : September 2007
Actual Primary Completion Date : August 2010
Actual Study Completion Date : August 2010

Arm Intervention/treatment
Experimental: 1
Lintuzumab plus low dose cytarabine
Drug: Lintuzumab (SGN-33)
600 mg IV on days 1, 8, 15 and 22 of cycle 1 and days 1 and 15 of each subsequent 28-day cycle up to a maximum of 12 cycles.
Other Name: SGN-33

Drug: Low dose cytarabine
20 mg SC twice a day on days 1-10 of each 28 day cycle up to a maximum of 12 cycles.
Other Name: Ara-C, Cytosar

Active Comparator: 2
Placebo plus low dose cytarabine
Drug: Low dose cytarabine
20 mg SC twice a day on days 1-10 of each 28 day cycle up to a maximum of 12 cycles.
Other Name: Ara-C, Cytosar

Drug: Placebo
IV administration on days 1, 8, 15, and 22 of cycle 1 and days 1 and 15 of each subsequent 28-day cycle up to a maximum of 12 cycles

Primary Outcome Measures :
  1. Overall survival [ Time Frame: 12 months ]

Secondary Outcome Measures :
  1. Complete blood counts (CBC), Transfusion Requirements, Infections or Fevers of Unknown Origin Requiring Hospitalization or IV Antibiotics [ Time Frame: 13 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   60 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Untreated AML that occurred de novo, after prior exposure to chemotherapy for a separate malignancy, or evolved from an antecedent hematologic disorder.
  • After being informed of the potential benefits and risks of available treatment options, patients must have declined intensive chemotherapy for AML.
  • At least 20% blasts in blood or marrow.
  • Must have a minimum of 50% leukemic blasts that express CD33.
  • ECOG performance status score of 0 to 2.
  • WBC less than 30,000/µL

Exclusion Criteria:

  • No known diagnosis of acute promyelocytic leukemia or chronic myeloid leukemia.
  • No other active systemic malignancies treated with chemotherapy within the last 12 months.
  • Must not have received previous chemotherapy (except hydroxyurea) for AML.
  • Must not have significantly abnormal kidney or liver disease.
  • Must not have known human immunodeficiency virus (HIV).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00528333

Layout table for location information
United States, Alabama
Southern Cancer Center
Mobile, Alabama, United States, 36608
United States, California
Tower Cancer Research Foundation
Beverly Hills, California, United States, 90210
Glendale Memorial Hospital
Glendale, California, United States, 91204
Kenmar Research Institute
Los Angeles, California, United States, 90057
University of California Los Angeles
Los Angeles, California, United States, 90095-1678
Bay Area Cancer Research Group
Pleasant Hill, California, United States, 94523
United States, Colorado
University of Colorado Cancer Center
Aurora, Colorado, United States, 80045
United States, Florida
Lakeland Regional Cancer Center
Lakeland, Florida, United States, 33805
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States, 33612
United States, Illinois
Rush University Medical Center
Chicago, Illinois, United States, 60612
Joliet Oncology-Hematology Associates
Joliet, Illinois, United States, 60435
United States, Michigan
Michigan State University, Breslin Cancer Center
Lansing, Michigan, United States, 48910
United States, Montana
Billings Clinic Cancer Research
Billings, Montana, United States, 59101
United States, New York
Northshore University Hospital, Monter Cancer Center
Lake Success, New York, United States, 11042
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
United States, Ohio
Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
United States, Pennsylvania
Western Pennsylvania Cancer Institute
Pittsburgh, Pennsylvania, United States, 15224
United States, South Carolina
Cancer Centers of the Carolinas
Greenville, South Carolina, United States, 29601
United States, Texas
University of Texas, MD Anderson Cancer Center
Houston, Texas, United States, 77030
United States, Wisconsin
Gunderson Clinic
La Crosse, Wisconsin, United States, 54601
Sponsors and Collaborators
Seattle Genetics, Inc.
Layout table for investigator information
Study Director: Eric Sievers, MD Seattle Genetics, Inc.

Publications of Results:
Layout table for additonal information
Responsible Party: Seattle Genetics, Inc. Identifier: NCT00528333     History of Changes
Other Study ID Numbers: SG033-0003
First Posted: September 12, 2007    Key Record Dates
Last Update Posted: January 7, 2015
Last Verified: December 2014

Keywords provided by Seattle Genetics, Inc.:
Antigens, CD33
Antibodies, Monoclonal
Leukemia, Myeloid, Acute
Hematologic Diseases

Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Leukemia, Myeloid
Antibodies, Monoclonal
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents, Immunological